| 引用本文： |
-
阿卜拉·太外库力,周永新,梅运清.PD-1/PD-L1免疫检查点抑制剂在食管癌治疗中的进展[J].同济大学学报（医学版）,2022,43(5):725-733. [点击复制]
- ABULA·Taiwaikuli,ZHOU Yongxin,MEI Yunqing.Progress of PD-1/PD-L1 immune checkpoint inhibitors in the treatment of esophageal cancer[J].Journal of Tongji University(Medical Science),2022,43(5):725-733. [点击复制]
|
|
| 摘要: |
| 食管癌（esophageal cancer， EC）是我国常见的一种恶性肿瘤，临床主要以手术及放化疗为主，但患者生存率没有明显改变。近几年，免疫治疗开创了EC治疗的新篇章。采用免疫治疗与化疗或放疗联合治疗策略可以提高EC的治疗效果。程序性死亡受体-1(programmed death-1， PD-1)/程序性死亡配体-1(programmed death ligand-1， PD-L1)检查点抑制剂作为EC免疫治疗的重要组成部分，本文围绕PD-1/PD-L1抑制剂在EC治疗上的研究进展及治疗过程中相关生物标志物的变化进行综述。 |
| 关键词: 食管癌 免疫治疗 免疫检查点抑制剂 |
| DOI：10.12289/j.issn.1008-0392.21483 |
| 通信作者: |
| 投稿时间：2021-11-10 |
| 录用日期： |
| 基金项目:上海市科学技术委员会项目（20S31904700） |
|
| Progress of PD-1/PD-L1 immune checkpoint inhibitors in the treatment of esophageal cancer |
| ABULA·Taiwaikuli,ZHOU Yongxin,MEI Yunqing |
| (School of Medicine， Tongji University， Shanghai 200092， China;Department of Cardiothoracic Surgery， Tongji Hospital， School of Medicine， Tongji University， Shanghai 200065， China;Department of Thoracic Surgery， Kashgar First People’s Hospital， Kashi 844000， Xinjiang Uygur Autonomous Region, China) |
| Abstract: |
| Esophageal cancer(EC) is one of the common digestive system malignant tumors in China, surgery, radiotherapy and chemotherapy have been the main therapeutic treatments for EC. In recent years, the cancer immunotherapy provides a new modality for EC therapy. Studies indicated that the combination of immunotherapy with chemotherapy or radiotherapy are able to improve the anti-tumor efficacy for cancer patients. PD-1/PD-L1 immune checkpoint inhibitor therapy as a major modality of immunotherapy has been used for EC treatment. In this article we review the recent progress of PD-1/PD-L1 inhibitor therapy and its application and related biomarkers in EC treatment. |
| Key words: esophageal cancer immunotherapy immune checkpoint inhibitor |
